154775-43-6

Basic information

• Product Name: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID
• Synonyms: Boc-piperidine-4-propanoic acid;3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid;3-(1-tert-Butoxycarbonyl-4-piperidyl)propanoic acid;1-Boc-4-piperidinepropanoic acid;4-Piperidinepropanoic acid, 1-[(1,1-dimethylethoxy)carbonyl]-;N-Boc-piperidin-4-ylpropionic acid;N-BOC-PIPERIDINYL-4-PROPIONIC ACID;1-BOC-PIPERIDINE-4-PROPANOIC ACID
• CAS NO: 154775-43-6
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: pharmacetical
• Mol File: 154775-43-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 386.4 °C at 760 mmHg
• Flash Point: 187.5 °C
• Appearance: /
• Density: 1.102 g/cm³
• Vapor Pressure: 4.83E-07mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 4.73±0.10(Predicted)
• CAS DataBase Reference: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(154775-43-6)
• EPA Substance Registry System: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(154775-43-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 154775-43-6(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(17)14-8-6-10(7-9-14)4-5-11(15)16/h10H,4-9H2,1-3H3,(H,15,16)/p-1

Upstream product

• 1822-32-8 3-(4-piperidyl)propionic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51052-79-0 3-(4-piperidinyl)propionic acid hydrochloride 
• 301185-77-3 3-(1-(t-butoxycarbonyl)-4-piperidylidene)propionic acid 
• 5337-79-1 3-(4-pyridinyl)-2-propenoic acid 
• 166815-97-0 1-(tert-butoxycarbonyl)-4-[2,2-di(ethoxycarbonyl)ethyl]piperidine 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 98488-12-1 trans-3-(4'-pyridyl)acrylic acid hydrochloride 
• 71879-55-5 ethyl 3-(piperid-4-yl)propionate 
• 123293-78-7 ethyl 3-(4-pyridinyl)-(2E)-propenoate 
• 473987-06-3 ethyl 3-(4-piperidinyl)propanoate hydrochloride 
• 872-85-5 pyridine-4-carbaldehyde 

Downstream Products

• 305328-96-5 4-(3-benzylsulfanyl-2-carboxypropyl)piperidine-1-carboxylic acid tert-butyl ester 
• 407640-41-9 Tert-butyl 4-[3-({[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-3-oxopropyl]piperdine-1-carboxylate 
• 162504-75-8 tert-butyl 4-(3-methoxy-3-oxopropyl)piperidine-1-carboxylate 

Relevant articles and documents

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.